EP2920292A2 - Vorrichtung und verfahren für dreidimensionale gewebemessungen auf basis eines kontrollierten medienstroms - Google Patents

Vorrichtung und verfahren für dreidimensionale gewebemessungen auf basis eines kontrollierten medienstroms

Info

Publication number
EP2920292A2
EP2920292A2 EP13827054.1A EP13827054A EP2920292A2 EP 2920292 A2 EP2920292 A2 EP 2920292A2 EP 13827054 A EP13827054 A EP 13827054A EP 2920292 A2 EP2920292 A2 EP 2920292A2
Authority
EP
European Patent Office
Prior art keywords
sample
media
well
disposed
plunger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13827054.1A
Other languages
English (en)
French (fr)
Other versions
EP2920292B1 (de
Inventor
Paul MCGARR
Andy C. Neilson
Jay S. TEICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agilent Technologies Inc
Original Assignee
Seahorse Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seahorse Bioscience Inc filed Critical Seahorse Bioscience Inc
Publication of EP2920292A2 publication Critical patent/EP2920292A2/de
Application granted granted Critical
Publication of EP2920292B1 publication Critical patent/EP2920292B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00Constructional details, e.g. recesses, hinges
    • C12M23/02Form or structure of the vessel
    • C12M23/12Well or multiwell plates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5025Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02Membranes; Filters
    • C12M25/04Membranes; Filters in combination with well or multiwell plates, i.e. culture inserts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00Means for mixing, agitating or circulating fluids in the vessel
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10Perfusion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/32Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/645Specially adapted constructive features of fluorimeters
    • G01N21/6452Individual samples arranged in a regular 2D-array, e.g. multiwell plates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02Adapting objects or devices to another
    • B01L2200/026Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/04Closures and closing means
    • B01L2300/046Function or devices integrated in the closure
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0809Geometry, shape and general structure rectangular shaped
    • B01L2300/0829Multi-well plates; Microtitration plates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0478Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5085Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
    • B01L3/50853Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates with covers or lids

Definitions

  • the invention relates generally to apparatus and methods for conducting analysis of three-dimensional cell samples (e.g., tissue samples).
  • XF measurements are based on a method in which a small, temporary, measurement volume is created around the cells, or a sensor is placed in close proximity to the cells. Measurements under these conditions amplifies changes in concentrations allowing highly sensitive, time resolved measurements to be collected from a set of optical sensors. Once the measurement is made, the plunger (probe) is lifted and the medium around the cells is restored to its original condition.
  • This nondestructive method allows multiple measurements to be serially collected for a biological sample under various conditions of stimulation (basal, environmental change, compound stimulus).
  • OCR extracellular acidification rate
  • ECAR extracellular acidification rate
  • the instrument and methods described herein allow the measurement of bioenergetic parameters in tissue samples or cell populations, e.g., tumor tissue samples, to generate its metabolic profile, thereby enabling, for example, a better understanding of the mechanisms of malignant progression. Accordingly, embodiments of the invention enable testing of physiologically relevant hypotheses that to date could not be tested otherwise, for example, by enabling the measurement and quantification of phenotypic shifts in tumors.
  • Embodiments of the invention comprise an apparatus for conducting analysis of three-dimensional cell samples.
  • the apparatus may include a plate of wells that are loaded with tissue samples which are tested by placing the plate in a machine specifically adapted as disclosed herein to conduct assays in wells of the plate.
  • the plate typically defines a plurality of wells for holding respective samples and sample media, where at least one of the wells, typically the entire array of wells, includes a sample nesting site disposed therein.
  • a bore is disposed above the nesting site, the bore being dimensioned to interfit with a plunger that moves vertically down within the bore and within the sample media disposed in the well.
  • the structure also defines a media channel that is in fluid communication with the sample nesting site. The media channel permits media displaced by the plunger to flow through and expose the sample to fresh media as the plunger moves.
  • the plunger preferably moves relative to the nesting site to induce perfusion of media about the sample, preferably on both the down and up stroke.
  • the plunger and sample nesting site may move together to expose the sample to different regions of media.
  • the media channel may include a fluid path that returns media perfused about the sample back to media disposed in the well.
  • the bore, sample nesting site, and/or media channel may be defined by a removable well insert.
  • the sample nesting site may include a media permeable platform defined by or as a part of the removable well insert.
  • the well may include a sump in fluid communication with the media channel.
  • the sample nesting site may be disposed within the sump where media collects and flows through the media channel.
  • the media channel may include a fluid path defining a closed loop beneath the surface of media in the well to permit media perfusive flow about the sample on both upward and downward movement of a plunger within the bore.
  • a check valve may be included in the media channel to inhibit backflow of spent media from the channel to the sample during upward movement of the plunger.
  • the apparatus may include sensors for detecting the concentration of solutes secreted from or absorbed by the sample in the media disposed about the sample.
  • the sensors may be disposed at the bottom of at least one of the wells.
  • the sensors may comprise fluorophores sensitive to the concentration of one or more solutes in the media mounted on the plungers to measure in regions adjacent the tissue sample, for example, oxygen, CO 2 or H + concentration.
  • the sensors may comprise beads coated with specific binders of specific cytokines, chemokines, hormones, or other biomolecules absorbed by or secreted from the tissue which become immobilized on the beads.
  • the beads may be probed in situ in a sump in a well to enable detection of the concentrations of molecules of interest secreted or taken up by the tissue.
  • the beads may be separated from the media and analyzed.
  • spotted antibodies may be disposed in a bottom portion of the well in fluid connection with the media perfusing through the well. The spotted antibodies may be used to detect other molecules of interest.
  • the apparatus may include plungers adapted for reciprocating movement within the bores of respective wells.
  • fluorophore sensors may be disposed on the plungers for detecting the concentration of solutes in media disposed about the sample.
  • the sensors may measure the concentration of oxygen, carbon dioxide, and/or hydrogen ions dissolved in media about the sample.
  • the plurality of wells may define a multi-well plate including, for example, 24 or 96 wells.
  • a source of oxygen, carbon dioxide, and/or a biologically inert gas may be in fluid communication with media in a well or a headspace above the surface of media in the wells for controlling the composition of gas in the headspace or in the media.
  • a source of a solution of a biologically active substance may be in fluid communication with media in wells for exposing a sample to the substance.
  • a three-dimensional cell growth scaffold may be disposed on the sample nesting site.
  • inventions of the invention may include an apparatus for conducting analysis of three-dimensional cell samples.
  • the apparatus may include a well for holding a sample and sample media, the well including a sample nesting site.
  • a bore may be disposed above the nesting site, the bore being dimensioned to interfit with a plunger that moves vertically down within the bore and within media disposed in the well.
  • the apparatus may also include a media channel in fluid communication with the sample nesting site that permits media perfusion about the sample, and a plunger adapted for reciprocal movement in the bore to impel media perfusion about the sample.
  • the apparatus may optionally include a sensor for detecting the concentration of a dissolved media component in media about the sample nesting site.
  • embodiments of the invention feature an insert for a well of a culture plate for adapting the well to implement perfusion of a three-dimensional cell culture sample disposed therein.
  • the insert includes a structure defining (i) a sample nesting site comprising a media-permeable platform, and (ii) disposed thereabove a bore dimensioned to interfit with a plunger which moves vertically down within the bore and within media disposed in a well.
  • the insert may also define a media channel in fluid communication with the sample nesting site, which permits media perfusion about the sample impelled by a plunger.
  • the embodiments of the invention feature a method of experimenting with a three-dimensional cell culture sample, e.g., a tissue sample, biopsied sample, or cell scaffold holding cells, so as to maintain viability of the sample and exercise control over its microenvironment.
  • the method includes providing a structure defining a well including a sample nesting site, a bore dimensioned to interfit with a plunger disposed above the sample nesting site, a media channel in fluid communication with the sample nesting site, and a plunger adapted for reciprocal movement in the bore.
  • a sample is placed on the sample nesting site in medium within the well.
  • the plunger is moved within the bore to impel media flow about the sample and through the channel to perfuse the sample with media.
  • a gas may be added to the media or to headspace in the well above the media to modify the microenvironment about the sample by altering dissolved gas composition.
  • a solution of a biologically active substance such as a drug, drug candidate, or toxin may be added to the media to modify the
  • microenvironment about the sample by exposing the sample to the biologically active substance.
  • the concentration of one or more solutes in media about the sample may be measured.
  • a plurality of measurements separated in time may be made of the concentration of one or more solutes in media about the sample.
  • a metered amount of one or more gases and/or one or more solutes may be added to media in the well thereby setting the microenvironment in the medium about the sample to a predetermined point.
  • the microenvironment may be set to a hypoxic condition.
  • An oxygen scavenger may be added to the medium.
  • a human biopsied tissue sample may be placed on the nesting site, potential therapeutic drugs may be added to the media, and the effect of the drugs on the sample may be assessed.
  • the sample may be a tumor sample, and a metered amount of one or more gases and/or one or more solutes may be added to media in the well thereby to set the sample
  • microenvironment in the medium about the sample to a predetermined point simulating the microenvironment of the tumor sample in vivo.
  • the method may be multiplexed by providing a plurality of the wells including sample nesting sites, bores dimensioned to interfit with plungers disposed above the respective sample nesting sites, media channels in fluid communication with each of the sample nesting site, and plungers adapted for reciprocal movement in each of the bores.
  • Sample may be placed on the sample nesting sites in media within each of a plurality of wells.
  • the plurality of plungers may be moved within the bores to impel media flow about the samples and through the channels thereby to perfuse the samples with media.
  • the concentration of one or more solutes in media about the samples in the plurality of the wells may be measured one or more times.
  • Figures la and lb are schematic, cross sectional views of a single well of a multi-well plate, with a plunger in the down position (la) and up position (lb) and an insert disposed therein, in accordance with an embodiment of the invention.
  • Figure lc shows the bottom of the insert in cross section.
  • Figure Id is a schematic cross-sectional view of an insert and a bottom portion of the insert in accordance with an embodiment of the invention showing certain currently preferred dimensions.
  • Figures le and If are schematic cross sectional views of two embodiments of the lower portion of a single well of a multi-well plate with an insert disposed therein, showing a sample nesting site in a sump at the bottom of the well (le), and a sample nesting site (and nested scaffold) disposed on a screen at the bottom of the insert (If).
  • Figure lg is a schematic cross-sectional view of the structure of an alternative embodiment of the well of the invention showing a ring which acts as a check valve to inhibit backflow of spent media from the media channel to the sample site during upward movement of the plunger.
  • Figure 2 is a schematic cross sectional view of the lower portion of a single well of a multi-well plate with an insert disposed therein and a sample nested on the insert, showing beads for detecting biomolecules present in media perfused from the tissue sample disposed in the sump.
  • Figure 3 is a schematic cross sectional view of the lower portion of a single well of a multi-well plate with an insert disposed therein, a sample nested on the insert ("3D scaffold"), and a sensor disposed at the bottom of the well in a sump.
  • Figures 4a and4b are upright and inverted (respectively) exploded perspective views of a multi-well plate and a covered cartridge adapted to mate with the plate showing various features of the plate in accordance with an embodiment of the invention.
  • Figure 5 is a schematic cross sectional view of a well of a well plate including ports disposed thereover for controlling gas content in the well and pneumatically controlling addition of exogenous substances in solution.
  • Figure 6 is a schematic illustration of a measurement system and apparatus in accordance with an embodiment of the invention.
  • Figure 7 includes graphs and micrographs illustrating mitochondiral Stress Test results comparing 2D and 3D cultures of HCT116 cells.
  • Figure 8 includes graphs illustrating glucose response for single pancreatic islets measured in a prototype perfusion plate in accordance with an embodiment of the invention.
  • Figure 9 includes schematic cross sectional views and a top view of a well in which cells are allowed to coalesce in accordance with an embodiment of the invention.
  • Figure 10 includes graphs and micrographs illustrating the generation of scaffolded discs.
  • Figure 11 is a graph illustrating measured respiratory capacity of liver micro- tissue, as function of carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) concentration.
  • Embodiments of the invention enable the measurement of one or more properties of one or more three-dimensional cell samples (e.g., tissue samples, biopsied samples, or cell scaffolds holding cells) that are disposed in, for example, one or more wells of a multiwell plate.
  • Three-dimensional cell samples e.g., tissue samples, biopsied samples, or cell scaffolds holding cells
  • Plates of various specific forms embodying the invention and well inserts that adapt more conventional plates to structures embodying the invention may be designed by the skilled artisan in view of this disclosure, and may be manufactured using conventional molding techniques from polymeric materials such as polyethylene terephthalate or polystyrene.
  • Figures la-lg show removable inserts 100 alone (Fig. Id) or in place within a well 110, e.g., a single well of a multiwell plate.
  • the insert may define media perfusion channels 120 to facilitate perfusion 130 of media over a three-dimensional cell sample, e.g., tissue 140 disposed in the well.
  • the channels may comprise multiple passages formed within the body of the insert itself, or more preferably, comprise passages defined between the inner surface of the well and outer surface of the insert.
  • the perfusion channels may include a check valve which functions to limit backflow of media from the channels to the sample on the upward stroke of the plunger.
  • the insert may also include a sample nesting site 150 to receive a sample prior to insertion of the insert into the well.
  • the sample nesting site in some embodiments, is disposed in the well itself, e.g., in a depression or sump independent of the insert.
  • the insert or the body of the well itself defines a bore 150 which interfits with a plunger 160.
  • the plunger 160, well 110, and bore 150 are configured and dimensioned to fit together preferably so that insertion and reciprocation of the plunger into the well permits agitating and mixing of the medium.
  • the plunger and the bore fit together to induce perfusion as the plunger moves downwardly or upwardly and medium perfuses the sample and passes through the perfusion channels.
  • the plunger also may be configured to introduce one or more sensors 180 for monitoring the presence or concentration of one or more analytes in medium disposed in the well.
  • Information from the sensors 180 may be transmitted through a fiber-optic probe 182 disposed in the plunger 170.
  • a compound delivery structure 185 may be disposed above the well, enabling the introduction through, e.g., delivery ports, into the well of a biologically active substance or a gas into media surrounding the three-dimensional sample.
  • the bottom surface of the well 1 10 may define a depression that acts as a sump during use.
  • the depression may be used to orient and control the positioning of samples in the well and its bottom surface to serve as a sample nesting site 150.
  • the well may be one of many wells of a multiwell plate, that may be designed to a standard "Society for Biological Screening" SBS footprint having a 6 mm well diameter with the depression at the bottom of the well having a depth of, e.g., 0.5 mm and a diameter of, e.g., 3 mm.
  • the dimensions of the depression may be selected in view of the analysis to be performed in the well. For example, the volume should be sufficient to hold a sample.
  • the exemplary dimensions indicated above are suitable for holding a sample that is approximately 300 ⁇ thick. Other dimensions may be provided, depending on analytical needs.
  • the removable insert 100 may be generally cylindrical, and sized and configured to slide into the well with a slight interference fit to its interior wall. See Figure Id.
  • the insert may have a height hi of about 0.2 inches and an outer diameter OD of about 0.247 inches.
  • the height of the insert may be selected such that that the stroke distance defined by the length of the bore in which the plunger generates hydrostatic pressure, i.e., perfusion stroke 190, may be increased or decreased to control the perfusion volume.
  • the outer diameter of the insert may be selected to allow the insert to fit snugly in the well.
  • protrusions 195 may be disposed on the outer sidewall of the insert to help secure and center the insert in the well, providing an outer diameter OD' at some points of 0.251 inches.
  • the top edge of the insert may be thin, e.g., have a thickness tl of 0.002 inches, so as to aid in guiding the plunger into the insert.
  • the inner surface of the insert may have an upper tapered portion and a lower vertical portion defining a bore having a diameter dl of, e.g., 0.15 inches.
  • the upper tapered portion may define an opening having a diameter d2 of e.g., 0.1 inches.
  • the bottom of the bore of the insert may define an opening having a diameter d3 of, e.g., 0.080 inches.
  • the opening may include a media permeable platform, e.g., a screen, sized and located to support a scaffold holding a three-dimensional cell culture or tissue sample.
  • the insert defines a plurality of perfusion channels 120 that begin on the bottom of the insert and extend up the insert's outer diameter wall to form a channel such that fluid pumped through the opening having a diameter d3 during the downward stroke of the plunger can be exhausted to create perfusion across a sample.
  • Each perfusion channel may have a height h2 of, e.g., 0.004 inches.
  • One currently preferred set of dimensions would define a 3 mm plunger stroke within a 3 mm bore so that the displaced volume of the pump (a bit over 20 mm3 or 20 ⁇ ) is approximately 4 times the volume of the channels.
  • the plunger and insert are sized such that the plunger moves at least 20 ⁇ of media when inserted into the bore.
  • the snug fit of the insert 100 in the well 110 enables the insert to be held securely in place and, in use, may immobilize and orient the sample 140 in a sample nesting site 150 disposed in a small microchamber or sump formed by the interface created by the depression at the bottom of the well and a bottom portion of the insert.
  • the sump is in fluid communication with the perfusion channel 120, i.e., with the media channel, through which perfusion flow 130 takes place.
  • the media channel may lead to a drain for collection of spent media.
  • media may be moved by the media channel to a waste site rather than back into the well.
  • the sample nesting site 150 is disposed on the insert 100 itself.
  • the insert may comprise a screen 190 at the bottom of the bore 160, on which a tissue sample or scaffold 200 with cells may be placed.
  • the sample nesting site may be disposed on the plunger, e.g., rigidly suspended from its bottom surface, such that the sample nesting site moves together with the plunger to expose the sample to different regions of media. Accordingly a possible but not preferred configuration includes the suspension of the sample nesting site on the plunger.
  • Media channels that may be defined by the insert permits media displaced by the plunger to leave the proximity of the sample, e.g., by flowing up the perimeter walls through the annulus defined by an outer surface of the insert and an inner sidewall of the well.
  • the media channel may extend from a bottom portion of the insert to a higher portion of the insert.
  • the media channel may include a plurality, e.g., four, perfusion channels 120 defined in a bottom portion of the insert 100.
  • the perfusion channels may be indentations defined on a bottom surface of the insert.
  • perfusion channels may be cylindrical openings defined in the bottom portion of the insert.
  • Each of the media channels may define a fluid path that returns media perfused about the sample back to media disposed in the well, or alternatively to a waste reservoir.
  • the media channels are in fluid communication with the sample nesting site, permitting flow of media therethrough. The flow of media is impelled by the plunger 170, thereby permitting exposure of the sample to fresh media as the plunger moves.
  • the insert may include the sample nesting site 150.
  • the insert may include a media permeable platform, such as a screen 190, spanning the opening in a bottom surface of the insert.
  • the screen may be made from any number of materials, such as polymers such as polyethylene terephthalate (PET) or polystyrene, cellulose, paper, etc., and attached by ultrasonic welding, heat staking, adhesives or mechanical entrapment.
  • PET polyethylene terephthalate
  • adhesion of the sample to the nesting site may be enhanced by using attachment promoters or tissue adhesives, such as MatriGelTM or Cell- TakTM.
  • the sample nesting site may be within the depression at the bottom of the well.
  • Each of the media channels may include a fluid path defining a closed loop beneath the surface of media in the well, permitting media perfusive flow about the sample on both upward and downward movement of the plunger within the bore.
  • the insert may be fabricated by injection molding.
  • Surface wettability may be increased by treatments known per se, e.g., performing a plasma pretreatment of the inserts to eliminate entrapment of gas bubbles in the perfusion channels by creating a more hydrophilic surface.
  • the bore preferably is situated above the nesting site, guides the plunger vertically down into the insert within the sample media disposed in the well, and creates hydrostatic pressure and media movement about the sample.
  • the plunger may be adapted for reciprocating movement within the bore disposed in the well, e.g., the bore defined by the insert.
  • Figure la illustrates a plunger 170 extended into the bore 160, in close proximity to the sample, while Figure lb illustrates the plunger 170 somewhat retracted.
  • a volume of media is forced via hydrostatic pressure across the tissue or scaffold and up (or down) the perimeter walls between the insert and the inner surface of the well.
  • Figure lg shows one form of a check valve 210 for inhibiting backflow of media from the perfusion channels to the sample on upstroke of the plunger.
  • the optional check valve 210 takes the form of a free floating annular ring comprising, e.g., an elastomeric polymer, that fits over the annular opening of the channels within the body of culture medium.
  • hydrostatic pressure from the channels displaces the ring and permits flow of spent media upwardly and radially inwardly to mix back into the volume of media in the well.
  • suction holds the ring in substantial sealing
  • the sample nesting site may include a scaffold 200 attached to the insert or to the bottom of the sump.
  • a scaffold is a three-dimensional porous solid such as a collagen membrane that mimics the parenchyma of tissue and its surrounding structure in vivo.
  • Such scaffolds are available commercially and may be fabricated from gels or fibrous/porous media, e.g., Alvetex®Scaffold or 3D BioTek scaffold material.
  • Alvetex®Scaffold is a highly porous, cross-linked polystyrene scaffold that has been section into 200 ⁇ thick membrane. The resulting material is inert and does not degrade during normal use. It has been adapted to fit a variety of conventional cell culture plastic -ware formats. Alvetex®Scaffold provides a suitable 3D structure in which cells can proliferate, migrate, differentiate, and function in an appropriate niche environment. Cells maintain a 3D shape and form close interactions with adjacent cells.
  • beads 220 comprising specific binders to biomolecules of interest may be disposed in the well 1 10 beneath or adjacent the sample as a means to assist with sample analysis.
  • the scaffold 200 or tissue may be immobilized to the insert so that media can perfuse through and around it.
  • the media contains, for example, key nutrients, signaling molecules, drugs, etc.
  • Beads such as are available from Luminex® containing an attachment molecule may be placed at the bottom of the well, such that multiple signaling molecules may be captured and subsequently detected or quantitated.
  • One may take advantage of the sump and small volume of media in intimate contact with the sample effectively to amplify the concentration of the signaling molecules and to capture them on the beads.
  • the beads preferably stay at the bottom of the well because they are trapped between the scaffold and the small channels around the perimeter.
  • the insert or array of inserts may be removed, and the beads can be read using known techniques, e.g., analyzed in a flow cytometer.
  • the apparatus preferably includes sensors 180, in addition to the optional beads described above, e.g., disposed on the plungers, for detecting the concentration of solutes in media disposed about the sample.
  • the sensors may measure the concentration of dissolved oxygen, carbon dioxide, or hydrogen ions in media about the sample. Measurements spaced in time permit assessment of the health or metabolic efficiency of the sample under various condition of its microenvironment.
  • sensors 180 may be placed at the bottom of a well or the sump to detect the concentration of solutes in the media
  • one may dispose an (3 ⁇ 4 or a pH sensor in the space between the bottom of the insert 100 and the bottom of the well 1 10.
  • Plates with sensors are commercially available, but the drawback is that one has to grow the cells on the sensor.
  • Kits with water soluble sensors to put into the media are also available, but also present disadvantages.
  • the embodiment described herein allows microwell plates to be provided with sensors on the bottom and an insert thereabove, allowing the microwell plate to be read in a standard plate reader, e.g., the BioTek Synergy line of plate readers.
  • These types of sensor configuration may be used with scaffolds or two-or three dimensional cultures grown on a membrane.
  • sensors may be utilized with the apparatus depending on the analysis to be performed and its selected configuration, including oxygen sensors, such as oxygen-quenched fluorescent sensors, pH sensors, including fluorescent sensors, ISFET and impedance sensors, CO 2 sensors, including bicarbonate buffer coupled and ammonium dye coupled fluorescent sensors as well as other CO 2 sensors; various ion and small molecule sensors; large molecule sensors including surface plasmon resonance sensors and sensors exploiting the principle of Wood's anomaly; acoustic sensors; and microwave sensors.
  • oxygen sensors such as oxygen-quenched fluorescent sensors, pH sensors, including fluorescent sensors, ISFET and impedance sensors, CO 2 sensors, including bicarbonate buffer coupled and ammonium dye coupled fluorescent sensors as well as other CO 2 sensors; various ion and small molecule sensors; large molecule sensors including surface plasmon resonance sensors and sensors exploiting the principle of Wood's anomaly; acoustic sensors; and microwave sensors.
  • a conventional plate reader may be used.
  • Preferred sensors are fluorophores. Many fluorescent sensing compounds and preparations are described in the art and many are available commercially from, for example, Molecular Probes Inc. and Frontier Scientific, Inc.
  • the currently preferred oxygen sensor is a fluorophore with the signal inversely proportional to oxygen concentration such as a porphyrin or rhodamine compounds immobilized as a particle or homogenously distributed in an oxygen permeable polymer, e.g., silicone rubber.
  • the currently preferred compound is porphyrin.
  • the currently preferred pH sensor is a fluorescent indicator dye, fluorescein, whose signal decreases upon protonation of the dye, and which is either entrapped in a particle that is suspended in a carrier polymer, or covalently attached to a hydrophilic polymer.
  • Useful fluorescent CO 2 indicator sensor typically are based on a pH sensitive transducer, with the fluorescence being indirectly modulated by the production of carbonic acid due to reaction of carbon dioxide with water. See, e.g., O.S.Wolf eis, Anal. Chem. 2002, 74, 2663-2678.
  • a fluorophore that detects glucose also can be used, such as one based on a non-enzymatic transduction using a boronic probe that complexes with glucose, resulting in a charge transfer that modulates the fluorescence of the probe, or an enzymatic glucose transducer that couples a glucose oxidase to a fluorescent oxygen sensor, with the binding and oxidation of glucose resulting in a quantitative modulation of the oxygen sensor. It also is within the scope of embodiments of the invention to employ a fluorophore or other type of sensor sensitive to biological molecules such as, for example, lactate, ammonia, or urea.
  • a lactate sensor can be based on an enzymatic sensor configuration, with lactate oxidase coupled to a fluorescent oxygen sensor, and with the binding and oxidation of lactate resulting in a quantitative modulation of the oxygen sensor.
  • An ammonia or ammonium ion sensor can be configured with immobilization of a protonated pH indicator in a hydrophobic, gas permeable polymer, with the fluorescence output quantitatively modulated by reaction with transient ammonia.
  • a urea sensor can be based on an enzymatic sensor configuration, with urease coupled to a fluorescent ammonia transducer, and with the binding and reduction of urea to ammonia, resulting in modulation of the ammonia sensor fluorescence.
  • the insert guides the plunger to provide perfusion by creating hydrostatic pressure in the column of medium above the tissue sample in the insert and/or in the depression at the bottom of the well.
  • the plunger reciprocates vertically through the column, medium is forced to flow across and sometimes through the tissue and exits the chamber through a series of channels around the perimeter of the insert and upwardly between the outer surface of the insert and the inner wall of the well.
  • By moving the plunger up and down medium is moved across the tissue, replenishing nutrients, providing oxygen, and sweeping away wastes.
  • the microenvironment around the sample may be continuously perfused between measurements.
  • the plunger moves into the bottom position, resting on or just above the insert, its motion is stopped, the small transient volume is created, and measurements are made.
  • Efficiency of perfusion through the insert may be increased by altering the stroke height, speed and clearances between the plunger and the insert.
  • a well plate configuration suitable for receiving the inserts described above and practicing embodiments of the invention comprises a wellplate 400 defining a plurality of wells 110.
  • the wellplate may be combined with a cartridge 410 and removable cover 420.
  • multiwell plate 400 has 24 wells.
  • the number of wells 110 in a plate may vary from 1 to several thousand. In some embodiments, a single well of nearly any size may be fabricated, or multiple wells may be fabricated, or multiple wells may be fabricated in a one- or two-dimensional arrangement.
  • the cartridge 410 is a generally planar element comprising a frame 430 made, e.g., from molded plastics.
  • Planar surface 440 defines a plurality of regions 450 that correspond to, i.e., register with, a number of the respective openings of a plurality of wells 110 defined in the multiwell plate 400.
  • the planar element defines first, second, third, and fourth ports 460, which serve as reservoirs for delivery of gases or reagents, and a central aperture 470 to a plunger 170.
  • Each of the ports is adapted to hold and to release on demand a test fluid to the respective well 1 10 beneath it.
  • the ports 460 are sized and positioned so that groups of four ports may be positioned over the wells 1 10, and a gas or test fluid from any one of the four ports may be delivered to a respective well 1 10.
  • the number of ports in each region may be less than four or greater than four.
  • the ports 460 and plungers 170 may be compliantly mounted relative to the microplate 400 so as to permit it to nest within the microplate by accommodating lateral movement.
  • the construction of the microplate to include compliant regions permits its manufacture to looser tolerances, and permits the cartridge to be used with slightly differently dimensioned microplates. Compliance can be achieved, for example, by using an elastomeric polymer to form planar element 440, so as to permit relative movement between frame 430 and the plungers and ports in each region.
  • Each of the ports 460 may have a cylindrical, conic or cubic shape, open through planar element 430 at the top, and closed at the bottom except for a small hole, i.e., a capillary aperture, typically centered within the bottom surface.
  • the capillary aperture is adapted to retain test fluid in the port, e.g., by surface tension, absent an external force, such as a positive pressure differential force, a negative pressure differential force, or possibly a centrifugal force.
  • Each port may be fabricated from a polymer material that is impervious to gasses, test compounds, or from any other solid material. When configured for use with a multiwell microplate 400, the liquid volume contained by each port may range from 500 ⁇ to as little as 2 ⁇ , although volumes outside this range are contemplated.
  • a submersible plunger 170 i.e., sensor sleeve or barrier
  • Plunger 170 may have one or more sensors 180 disposed on a lower surface thereof for insertion into media in a well 1 10.
  • the sensor can be used to detect the concentration of a dissolved media component in media about the sample nesting site.
  • a fluorescent indicator such as an oxygen-quenched fluorophore, embedded in an oxygen permeable substance, such as silicone rubber.
  • the fluorophore has fluorescent properties dependent on the presence and/or concentration of a constituent in the well 110.
  • Other types of known sensors may be used as described above, such as electrochemical sensors, Clark electrodes, etc.
  • Plunger 170 may define an aperture and an internal volume adapted to receive a sensor.
  • the cartridge 410 may be attached to the plunger, or may be located proximal to the plunger without attachment, to allow independent movement.
  • the cartridge 410 may include an array of compound storage and delivery ports assembled into a single unit and associated with a similar array of plungers.
  • the apparatus may also feature a removable cover 420 for the cartridge 110 or for multiwell plate 400.
  • the configuration of cartridge 110 as a cover for multiwell plate 400 may help prevent evaporation or contamination of a sample or media disposed in wells 1 10.
  • the cover 420 may also be configured to fit over the cartridge 1 10 thereby to reduce possible contamination, to maintain the content of the gas in the wells, or reduce evaporation of fluids disposed in the ports 460 of the cartridge 410.
  • Figure 5 depicts a schematic cross section of a well 1 10 of an embodiment of the invention showing structure 185 used to add drugs or gasses to wells so as to alter the microenvironment of the samples under examination. Details of the delivery system of the existing, commercially available Seahorse XF Analyzer are described in US 20080014571, the disclosure of which is incorporated herein by reference.
  • the drug delivery manifold 510 may be modified to deliver environmental gases, e.g., an external gas 520, i.e., from a gas cylinder, or internal air 530 to the head space directly above each well.
  • the internal air may be, e.g., ambient air from inside the instrument that is compressed via a small internal compressor, to pressurize the drug ports to deliver drug compounds.
  • the delivery of gas to the head space may allow manipulation of the environment around the test sample to create conditions simulating hypoxia ( ⁇ 5% (3 ⁇ 4) or normoxia and/or low pH.
  • a source of oxygen, carbon dioxide, and/or a biologically inert gas may be injected into media in the well or a headspace above the surface of media in the wells for controlling the composition of gas in the headspace or in the media.
  • the gas may be injected into the media or headspace from ports 460.
  • a cartridge 410 contains a set of 4 ports 460 that may be used to deliver various compounds to the sample within the wellplate.
  • a common test performed on the XF instrument is a mitochondrial stress test.
  • a series of injections are delivered through the drug ports of the cartridge in order to measure the response of the biological sample to various compounds (oligomycin, FCCP, rotenone and antimycin). These compounds are preloaded into a drug reservoir (port) on the XF cartridge prior to execution of the assay.
  • a manifold When the cartridge is inserted into the instrument it is coupled to a manifold which when activated by a solenoid valve, provides pneumatic pressure to the head space of the reservoir forcing the compound through a small orifice and into the well containing the biological sample.
  • the pneumatic manifold and valve system may be modified to redirect one of these ports to an external gas supply (gas cylinder or bottle).
  • the gas supply may be connected to the instrument through a port on the rear connector panel.
  • the bottle may be located near the instrument and may contain a regulator and bubbler for humidification of the incoming gas.
  • a solenoid valve When activated, a solenoid valve may open, allowing the gas to flow through the manifold/cartridge interface, through the drug port orifice, and into the head space above the biological sample.
  • the gas By oscillating the plunger (probe) vertically, the gas will be mixed with the medium allowing control of the available oxygen to the sample. For example, by perfusing argon into the head space, the available (3 ⁇ 4 in the medium is displaced and a more hypoxic condition is created around the sample. By turning off the gas and mixing, ambient levels of O2 may be re-established.
  • a source of a solution of a biologically active substance may be in fluid communication with media in wells for exposing a sample to the substance
  • the instrument software may be modified to facilitate control of the valve/timing and to expose some of the calculation variables used during calibration.
  • the concentration at calibration is preferably known and input into the calculation table.
  • the initial calibration value F or current ambient concentration
  • calibration and solution of equation (1) may be achieved by injecting sodium sulfite into a set of control wells and calibrating the system based on a known F0 value.
  • certain coefficients may be made accessible in the software. A separate window may be created in the software to facilitate access to these variables, valve control and calculation of calibration coefficients.
  • the instrument may be tested using a well characterized cell line (mouse C2C12) to verify proper operation and control of the gas system.
  • a series of tests may be conducted to demonstrate the ability to purge O2 from medium and create a hypoxic microenvironment around the sample. These tests may include:
  • An alternative to controlling O2 and pH within the sample environment may be to enclose the entire instrument in an environmental chamber and pump down the chamber to the desired levels.
  • This alternative approach may be less desirable, as it may be very costly, take up a lot of lab space, and require long periods of time to achieve the desired levels around the tissue. By the time these O2 levels are achieved the tissue may be dead.
  • Figure 6 shows a schematic of an analyzer used in connection with embodiments of the invention. It comprises an apparatus 600 including a compound storage and delivery apparatus 610 disposed in a housing 615(shown in dashed lines) and includes a cartridge 410 defining a plurality of apertures for receiving sensor structures and a plurality of fluid ports (shown in detail in Figs. 4a and 4b) compliantly mounted, and a stage or base 130 adapted to receive a multiwell plate 400, e.g., a cell culture plate.
  • the cartridge 410 is disposed above, and adapted to mate with, the multiwell plate 400.
  • the cartridge 410 optionally is held by a cartridge holder 630 adapted to receive the cartridge 410.
  • the apparatus also includes a mounting block 640, which can reciprocate as shown by the double headed arrow, preferably powered by a motor (not shown), including an elevator mechanism 650.
  • the elevator mechanism 650 may be adapted to move the cartridge 410 relative to the stage 620, or well plate 400.
  • the mounting block includes a gas multiplexer 660 attached to a gas supply or gas reservoir 670.
  • the gas supply 670 is in fluid communication with the cartridge, and is used to impel the delivery of test fluid from a port in the cartridge to a well in the multiwell plate 400, or to fix the gas composition in one or more wells.
  • a plurality of probes or plungers 170 with sensors are adapted for insertion into the plurality of apertures in the cartridge 410, and may be used to gather data indicative of the state of cells disposed in wells in the multiwell plate 400.
  • the compound storage and delivery apparatus 610 is controlled by a controller 680, that may be integrated with a computer 690, that may control the elevator mechanism, the multiplexer, and the pressure source.
  • the controller 680 may, thereby, permit delivery of a test fluid from a port to a corresponding well when an associated sensor is disposed in the well.
  • US 20080014571 referenced above, and enables experimentation with and analysis of three- dimensional cell culture samples, such as a tissue sample, a biopsied sample, or a cell scaffold holding cells. Viability of the sample may be maintained and control exercised over its microenvironment.
  • a gas may be added to the media or to a headspace in the well above the media to modify the microenvironment about the sample by altering dissolved gas composition.
  • a solution of a biologically active substance may be added to the media to modify the microenvironment about the sample by exposing the sample to a biologically active substance.
  • a metered amount of one or more gases and/or one or more drugs or other solutes may be added to media in the well to set the microenvironment in the medium about the sample to a predetermined point.
  • microenvironment in the well may be set to a hypoxic condition.
  • concentration of one or more solutes in media about the sample may be measured.
  • a plurality of measurements, separated in time, of the concentration of one or more solutes in media about the sample may be taken.
  • the method includes adding an oxygen scavenger such as sodium sulfite to the medium.
  • a human biopsied tissue sample may be placed on the nesting site, potential therapeutic drugs may be added to the media, and the effect of the drugs on the sample may be assessed.
  • Example 1 Development of a custom injection molded wellplate and perfusion insert designed for tissue perfusion and immobilization.
  • the Seahorse XF96 flux analyzer was developed and optimized to measure bio- energetic activity in cell based assays. XF measurements are based on a patented method in which a small, temporary measurement volume is created around a monolayer of cells which are adherent to the bottom of the wellplate. A small volume is created when the plunger (probe) is lowered to the bottom of the well (3.8 mm diameter) and engages a set of standoffs (0.20 mm height) to create a volume of approximately 2.25 microliters.
  • the present design of the wellplate is not optimal for use with tissue samples because: (1) samples need to be immobilized and orientated to prevent them from shifting between measurements, (2) lack of a consistent and homogeneous supply of nutrients (perfusion) of the three-dimensional samples, and (3) a larger measurement chamber is required that will accommodate samples up to 200 micrometers thick.
  • a disposable 96-well plate and plunger (probe) system to work within the Seahorse XF96 instrument that immobilizes, orientates, and provides perfusion of tissue samples.
  • the custom wellplate and perfusion inserts described above are suitable for use with tissue samples.
  • the wellplate may be designed to a standard "Society for Biological Screening" SBS footprint having a 6 mm well diameter with a depression at the bottom of the well 0.5 mm deep, 3 mm diameter, used to orient and control the positioning of samples in the depression at the bottom of the well.
  • the perfusion inserts are designed to slide into the well, with a slight interference to the wall so that the insert is held in place over the sample, and to immobilized the sample in the depression at the bottom of the well.
  • a wellplate, inserts, and plungers may be assembled and installed in a specialized heatsink that provides alignment and thermal control of the samples.
  • Appropriate position offsets and a calibration protocol for the sensors may be developed.
  • the calibration protocol consists of determining the appropriate volumes, diffusion constants, and sensor gains that are unique to the plate, insert, and probe geometry. These constants may be calculated using calibration reagents titrated to known concentrations to develop a set of coefficients that describe the signal outputs as a function of analyte concentration (0 2 or H + ).
  • the optical signals (based on a 16 bit readout) are normalized to a starting H + concentration (pH 7.4) by determining the excitation intensity for each probe that provides a desired starting signal at pH 7.4.
  • the signal at different H concentration is recorded to develop a standard curve.
  • the coefficients for the standard curve are then loaded into the instrument so that each sensor is calibrated over a range of concentrations to be measured.
  • the Stern Volmer quenching constant may be calculated based on equation 1 below and this relationship used to calculate the (3 ⁇ 4 level at each time point during the experiment.
  • a series of tests may be conducted to determine the best geometry for the perfusion inserts. These tests may involve taking repeated OCR/ECAR measurements of a standard, well characterized cell line such as C2C12 fibroblasts. After each measurement the plungers (probes) may be oscillated to perfuse the measurement chamber and optimize the timing, Z travel, and speed to get the best perfusion. The best perfusion may be determined based on the ability of the system to restore the measurement chamber to the starting concentration of O 2 and pH.
  • a prototype device was fabricated to evaluate various geometric properties and applications of embodiments of the invention, as discussed below in examples 4-6.
  • the device includes a plurality of cylindrical vessels fitted with a polycarbonate perfusion insert.
  • the insert is fitted to the bottom of the vessel to form a pair of chambers within the vessel that are connected through a 1.5 mm port.
  • the upper chamber consists of a reservoir of media which is approximately 30 times the volume of the lower chamber.
  • the inside diameter of the insert engages the Seahorse sensor cartridge to form a piston-like pump having a stroke length of approximately 5 mm and a diameter of 3 mm.
  • the plunger of the Seahorse sensor cartridge when moved through the inner diameter of the insert, forces media from the upper section of the chamber, through the port, into the lower chamber from which it exits through a set of peripheral vents between the inside diameter of the vessel and the outside diameter of the insert.
  • a volume of fluid is perfused through the lower chamber such that the fluid turnover is a minimum of 2 times the static volume.
  • a depression in the vessel (1 mm x 0.25 mm) where, during use, a spherical micro-tissue is positioned for measurement.
  • the cartridge comes to rest on a surface where the sensors are positioned in the center of the port which isolates the top chamber from the bottom chamber.
  • the sensors are thus positioned over the micro-tissue, sealing the lower chamber from the upper chamber. Within this reduced volume of fluid, measurements are collected from the sensors to record the oxygen and pH concentrations at various timed intervals. From this data the oxygen and pH flux (dO/dT), (dpH/dT) are determined. This method has been used to evaluate the geometric properties of the insert to optimize fluid turnover while maintaining tissue position and to facilitate measurements of the metabolic properties of the tissues.
  • HTC116 colon carcinoma cells grown in 2D mono-layer culture are compared to cells formed in a 3D Spheroid (using the hanging drop method) using a Seahorse Bioscience Mitochondrial Stress Test (MST).
  • MST Seahorse Bioscience Mitochondrial Stress Test
  • the spheroid image on the right shows a single micro-tissue sitting in the 1 mm x 0.25 mm relief in the bottom of the well (size approximately 200 microns).
  • the signatures reveal distinct differences in the spare respiratory capacity between the two culture types (maximum respiration, basal).
  • this data may be correlated to a set of glucagon and insulin biomarkers co-located in the in the perfusion path using an in situ ELISA assay to correlate oxygen consumption to insulin and glucagon secretion.
  • 3D micro-tissues ranging in size from 50-600 microns have been generated.
  • cells are seeded with 40 ⁇ of media into a commercially available seeding lid provided by InSphero Bioscience (Zurich, Switzerland).
  • ECMs extra cellular matrices
  • tissue generally consisting of protein matrices that define the micro-environment around the cell.
  • spheroids Once the spheroids are formed they are placed into storage plate with an additional 100 ⁇ of media where they are maintained until ready to use. Using this method, 3D spheroids have been generated from Hep G2's (human liver carcinoma) and HCT 1 16 (human colorectal carcinoma). These cell lines have been shown to form uniform sized spheroids both as monocultures and co-cultures. In addition, referring to Figure 10, scaffolded discs containing MCF-7 (breast ductal carcinoma) have been successfully generated.
  • MCF-7 breast ductal carcinoma
  • spheroids may be used to perform a test for
  • hepatocytes are co-cultured with non-parenchymal (Kupffer cell, etc.) cells to form a liver micro-tissue that presents a functional immune response.
  • the system is used to screen the tissues for toxicity by introducing FCCP and measuring respiratory capacity (FCCP stimulated vs basal OCR).
  • FCCP stimulated vs basal OCR respiratory capacity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Clinical Laboratory Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP13827054.1A 2012-11-13 2013-11-13 Vorrichtung und verfahren für dreidimensionale gewebemessungen auf basis eines kontrollierten medienstroms Active EP2920292B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725781P 2012-11-13 2012-11-13
PCT/US2013/069839 WO2014078379A2 (en) 2012-11-13 2013-11-13 Apparatus and methods for three-dimensional tissue measurements based on controlled media flow

Publications (2)

Publication Number Publication Date
EP2920292A2 true EP2920292A2 (de) 2015-09-23
EP2920292B1 EP2920292B1 (de) 2017-01-11

Family

ID=50069276

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13827054.1A Active EP2920292B1 (de) 2012-11-13 2013-11-13 Vorrichtung und verfahren für dreidimensionale gewebemessungen auf basis eines kontrollierten medienstroms

Country Status (5)

Country Link
US (1) US9494577B2 (de)
EP (1) EP2920292B1 (de)
JP (1) JP6326058B2 (de)
CN (1) CN104471052B (de)
WO (1) WO2014078379A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385700A1 (de) * 2017-04-06 2018-10-10 Agilent Technologies, Inc. Verfahren und vorrichtung zur messung physiologischer eigenschaften biologischer proben
EP4155709A1 (de) * 2021-09-28 2023-03-29 Bayer AG Biomolekulare online-interaktionsanalyse zur überwachung oder steuerung von bioprozessen

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505813C1 (ru) 2012-11-06 2014-01-27 Виктор Вениаминович Тец Способ определения чувствительности микроорганизмов к антимикробным веществам
US9790465B2 (en) 2013-04-30 2017-10-17 Corning Incorporated Spheroid cell culture well article and methods thereof
US20150050735A1 (en) * 2013-08-14 2015-02-19 3-D Matrix, Ltd. Well plates
EP3075840B1 (de) * 2013-11-28 2018-10-17 Viktor Veniaminovich Tets Verfahren zur bestimmung der empfindlichkeit von mikroorganismen gegenüber antimikrobiellen wirkstoffen
CN113481097A (zh) 2014-10-29 2021-10-08 康宁股份有限公司 灌注生物反应器平台
KR102460969B1 (ko) 2014-10-29 2022-10-31 코닝 인코포레이티드 세포 배양 인서트
JP6745076B2 (ja) * 2015-02-04 2020-08-26 サイティバ・スウェーデン・アクチボラグ 無菌で接続可能なセンサパッチ
US10746736B2 (en) 2015-03-26 2020-08-18 University Of Houston System Integrated functional and molecular profiling of cells
RU2604789C1 (ru) 2015-06-23 2016-12-10 Виктор Вениаминович Тец Питательная среда для выращивания бактерий
US20190086391A1 (en) 2016-03-08 2019-03-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and system for continuous biosensing
WO2018094194A1 (en) * 2016-11-17 2018-05-24 Cleveland State University Chip platforms for microarray 3d bioprinting
US10883978B2 (en) 2017-01-31 2021-01-05 Agilent Technologies, Inc. Method and device for calibration of biological flux
DE102017108022B4 (de) * 2017-04-13 2019-01-17 Universität Rostock Messbox zur Analyse von Substanzen
JP7195302B2 (ja) 2017-07-14 2022-12-23 コーニング インコーポレイテッド 3d培養のための細胞培養容器及び3d細胞の培養方法
CN111051494B (zh) 2017-07-14 2024-03-29 康宁股份有限公司 用于手动或自动培养基交换的3d细胞培养容器
PL3652291T3 (pl) 2017-07-14 2022-03-28 Corning Incorporated Naczynie do hodowli komórkowej
US11857970B2 (en) 2017-07-14 2024-01-02 Corning Incorporated Cell culture vessel
US11262349B2 (en) 2017-10-11 2022-03-01 Cleveland State University Multiplexed immune cell assays on a micropillar/microwell chip platform
EP3697889A4 (de) * 2017-10-19 2021-07-14 University of Pittsburgh - of The Commonwealth System of Higher Education Mehrachsige mechanische stimulationssysteme und inkubatoren
JPWO2019142913A1 (ja) * 2018-01-18 2021-03-04 国立大学法人 東京大学 3次元組織内のグルコース濃度マッピングのための蛍光マイクロ粒子
PL3649229T3 (pl) 2018-07-13 2021-12-06 Corning Incorporated Naczynia do hodowli komórkowych ze stabilizującymi urządzeniami
PL3649226T3 (pl) 2018-07-13 2022-05-16 Corning Incorporated Płytki mikrodołkowe z boczną ścianką zawierającą powierzchnię dostarczającą płynną pożywkę
EP3649227A1 (de) 2018-07-13 2020-05-13 Corning Incorporated Fluidische vorrichtungen mit mikroplatten mit untereinander verbundenen vertiefungen
EP3850336A4 (de) * 2018-09-14 2022-02-09 Illumina, Inc. Durchflusszellen und zugehörige verfahren
CN110961167B (zh) * 2018-09-29 2022-04-01 中国科学院微电子研究所 一种微流道网络芯片
US11591562B2 (en) * 2018-12-18 2023-02-28 Billups-Rothenberg, Inc. Modular oxygen monitor
US20230002713A1 (en) * 2019-11-19 2023-01-05 Jennifer Hui-Chun Ho Cell culture system and methods of using the same
WO2021193029A1 (ja) 2020-03-25 2021-09-30 Phcホールディングス株式会社 細胞培養分析装置およびこれを用いた細胞培養分析方法、添加剤供給部材およびこれを備えた細胞培養分析装置、センサユニットおよびこれを備えた細胞培養分析装置
US20240159672A1 (en) 2021-03-14 2024-05-16 Agilent Technologies, Inc. System and Method For Analyzing Biological Material
WO2023081354A1 (en) 2021-11-05 2023-05-11 Agilent Technologies, Inc. Apparatus and methods for generating and analyzing three-dimensional cellular materials
WO2023086372A1 (en) 2021-11-09 2023-05-19 Agilent Technologies, Inc. Wellplate apparatus and method for filling same
US20240050953A1 (en) * 2022-08-15 2024-02-15 U.S. Environmental Protection Agency Retention lid for stabilizing porous membrane inserts during manipulation

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065357A (en) 1974-01-21 1977-12-27 General Electric Company Detection of catalase-containing bacteria
FR2296476A1 (fr) 1975-01-06 1976-07-30 Cardus Francis Appareil electrique pour l'application d'un produit d'entretien ou de traitement
DE2711432A1 (de) 1977-03-16 1978-09-21 Bosch Gmbh Robert Zuendanlage, insbesondere fuer brennkraftmaschinen
USD258145S (en) 1978-03-23 1981-02-03 Corning Glass Works Stackable laboratory rack or the like
US4256832A (en) 1978-12-12 1981-03-17 Bioresearch Inc. Carcinogen and mutagen screening method and apparatus
USD260428S (en) 1979-03-15 1981-08-25 Abbott Laboratories Cuvette array or the like
US4405375A (en) 1980-05-21 1983-09-20 The B. F. Goodrich Company Niyuminouzbituminous emulsion roof resaturant
USD268130S (en) 1980-06-27 1983-03-01 Easton Harlan J Tray for veterinary supplies and equipment
USD280663S (en) 1981-11-17 1985-09-17 Internationale Octrooi Maatschappij "Octropa" B.V. Tray for carrying out chemical and biological tests
USD280131S (en) 1982-04-10 1985-08-13 Olympus Optical Co., Ltd. Case for a multiplicity of liquid sample containers for a multitest chemistry analyzer
US4461328A (en) 1982-06-04 1984-07-24 Drummond Scientific Company Pipette device
US4498510A (en) 1982-08-20 1985-02-12 Minshew Jr Edward C Device for drawing, holding and dispensing liquid
JPS59502060A (ja) 1982-11-20 1984-12-13 ウイザ−ド,ト−マス・パタ−ソン 試験記録装置
USD285118S (en) 1983-01-19 1986-08-12 Abbott Laboratories Sample cup
DE3321285C2 (de) 1983-06-13 1985-06-20 Anton 8240 Berchtesgaden Stigler Verfahren zum Herstellen eines Profils aus trockenem Pulvermaterial sowie Vorrichtung hierzu
US4599315A (en) 1983-09-13 1986-07-08 University Of California Regents Microdroplet test apparatus
US4711851A (en) 1984-05-21 1987-12-08 State University Of New York Test apparatus for determining a metabolic characteristic of microorganisms
USD300245S (en) 1986-08-14 1989-03-14 Sherwood Medical Company Microbiological test tray carrier
CA60693S (en) 1987-02-27 1988-04-26 Adi Diagnostics Inc Tray
US5001048A (en) 1987-06-05 1991-03-19 Aurthur D. Little, Inc. Electrical biosensor containing a biological receptor immobilized and stabilized in a protein film
US5286364A (en) 1987-06-08 1994-02-15 Rutgers University Surface-modified electochemical biosensor
JPH0292270A (ja) 1988-09-30 1990-04-03 Terumo Corp 細胞培養装置
ATE121790T1 (de) 1988-10-21 1995-05-15 Molecular Devices Corp Verfahren und apparat zur messung der effekte von zellwirksamen mitteln auf lebende zellen.
US5278048A (en) 1988-10-21 1994-01-11 Molecular Devices Corporation Methods for detecting the effect of cell affecting agents on living cells
US5200051A (en) 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5250419A (en) 1988-12-16 1993-10-05 L'oreal Method for the direct measurement of at least one chemical parameter of skin using a biosensor
US5156810A (en) 1989-06-15 1992-10-20 Biocircuits Corporation Biosensors employing electrical, optical and mechanical signals
US5491097A (en) 1989-06-15 1996-02-13 Biocircuits Corporation Analyte detection with multilayered bioelectronic conductivity sensors
USD324426S (en) 1989-10-20 1992-03-03 Pacific Biotech, Inc. Reaction unit for use in analyzing biological fluids
USD332145S (en) 1989-12-18 1992-12-29 Kurashiki Boseki Kabushiki Kaisha Centrifuge tube
USD328135S (en) 1990-01-12 1992-07-21 Pacific Biotech, Inc. Reaction unit for use in analyzing biological fluids
CA2140892A1 (en) 1992-07-29 1994-02-17 Patricia J. Malin An improved system for electronically monitoring and recording cell cultures
DE4016617A1 (de) 1990-05-23 1991-11-28 Rainer Dylla Objekttraeger fuer nasse oder feuchte praeparate, z. b. blut
US5104804A (en) 1990-06-04 1992-04-14 Molecular Devices Corporation Cell assay device used in a microphysiometer
KR930002824B1 (ko) 1990-08-21 1993-04-10 손병기 감이온 전계효과 트랜지스터를 이용한 바이오 센서용 측정회로
US5120421A (en) 1990-08-31 1992-06-09 The United States Of America As Represented By The United States Department Of Energy Electrochemical sensor/detector system and method
USD339869S (en) 1991-01-14 1993-09-28 Amgen, Inc. Vial container
AU647609B2 (en) 1991-04-18 1994-03-24 Becton Dickinson & Company Microbial monitoring device
US6395506B1 (en) 1991-04-18 2002-05-28 Becton, Dickinson And Company Device for monitoring cells
USD335348S (en) 1991-07-23 1993-05-04 Pb Diagnostic Systems Inc. Assay module magazine
US5264103A (en) 1991-10-18 1993-11-23 Matsushita Electric Industrial Co., Ltd. Biosensor and a method for measuring a concentration of a substrate in a sample
CA2121797A1 (en) 1991-10-21 1993-04-29 James W. Holm-Kennedy Method and device for biochemical sensing
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
US5370842A (en) 1991-11-29 1994-12-06 Canon Kabushiki Kaisha Sample measuring device and sample measuring system
DE4217868C2 (de) 1992-05-29 1995-01-26 Univ Schiller Jena Temperierbare Multiküvette
US5345213A (en) 1992-10-26 1994-09-06 The United States Of America, As Represented By The Secretary Of Commerce Temperature-controlled, micromachined arrays for chemical sensor fabrication and operation
USD351661S (en) 1993-02-16 1994-10-18 Ultradent Products, Inc. Combined organizer and tray for an endodontic dental kit
US5459300A (en) 1993-03-03 1995-10-17 Kasman; David H. Microplate heater for providing uniform heating regardless of the geometry of the microplates
US5512492A (en) 1993-05-18 1996-04-30 University Of Utah Research Foundation Waveguide immunosensor with coating chemistry providing enhanced sensitivity
DE4318519C2 (de) 1993-06-03 1996-11-28 Fraunhofer Ges Forschung Elektrochemischer Sensor
US5766875A (en) 1993-07-30 1998-06-16 Molecular Devices Corporation Metabolic monitoring of cells in a microplate reader
USD359125S (en) 1993-09-28 1995-06-06 Becton Dickinson And Company Microbial monitoring module
US5468605A (en) * 1993-10-15 1995-11-21 Molecular Devices Corp. Transverse flow plungers for microphysiometers
DE4405375C2 (de) 1994-02-19 1996-07-25 Fritz Nerbe Nachfolger Juergen Mikrotiterplatte
US5515864A (en) 1994-04-21 1996-05-14 Zuckerman; Ralph Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime
US6080574A (en) 1994-05-10 2000-06-27 Becton, Dickinson And Company Composite optical blood culture sensor
US5792426A (en) 1994-10-11 1998-08-11 Schweizerische Eidgenossenschaft Vertreten Durch Das Ac-Laboratorium Spiez Der Gruppe Rustung Multi-well titerplate for instrumental analysis
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
EP0722136A2 (de) 1995-01-12 1996-07-17 Joachim Schulz Thermoschüttler
DE19512117A1 (de) 1995-04-04 1996-10-10 Itt Ind Gmbh Deutsche Meßeinrichtung
USD404497S (en) 1995-09-27 1999-01-19 Becton Dickinson And Company Cell insert assembly
US6416967B2 (en) 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US20020168679A1 (en) 1998-06-11 2002-11-14 Gregory J. Naus Staining agents and protocols for characterizing malignant cells in culture
US5728541A (en) 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US8173438B1 (en) 1996-10-08 2012-05-08 Photonic Biosystems, Inc. Microbiological assessment method and device utilizing oxygen gradient sensing
CA2267897C (en) 1996-10-09 2005-12-06 Symyx Technologies Infrared spectroscopy and imaging of libraries
DE19646505A1 (de) 1996-11-12 1998-05-14 Itt Ind Gmbh Deutsche Vorrichtung zur Durchführung von Untersuchungen an Zellproben und dergleichen
US6083761A (en) 1996-12-02 2000-07-04 Glaxo Wellcome Inc. Method and apparatus for transferring and combining reagents
US5774214A (en) 1996-12-12 1998-06-30 Photometrics, Ltd. Multi-mode imaging apparatus for radiation-emitting or absorbing samples
US5830138A (en) 1996-12-16 1998-11-03 Trustees Of The University Of Pennsylvania Intravascular catheter probe for clinical oxygen, pH and CO2 measurement
USD404831S (en) 1997-04-21 1999-01-26 Hitachi, Ltd. Reagent bottle holder for a reagent disc
USD421498S (en) 1997-05-23 2000-03-07 Becton, Dickinson And Company Microbiological test panel
US6146967A (en) 1997-08-20 2000-11-14 Micron Technology, Inc. Selective deposition of amorphous silicon film seeded in a chlorine gas and a hydride gas ambient when forming a stacked capacitor with HSG
US6486947B2 (en) 1998-07-22 2002-11-26 Ljl Biosystems, Inc. Devices and methods for sample analysis
EP0921391A1 (de) 1997-12-05 1999-06-09 Interuniversitair Micro-Elektronica Centrum Vzw Vorrichtung und Verfahren zur thermischen Messung
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
AU4077499A (en) 1998-05-15 1999-12-06 Glaxo Group Limited Infrared thermography
US6881584B1 (en) 1998-05-15 2005-04-19 Smithkline Beecham Corporation Infrared thermography
US20020059945A1 (en) * 1998-05-29 2002-05-23 Romaine Maiefski Sample wash station assembly
US5998517A (en) 1998-06-05 1999-12-07 Becton, Dickinson And Company Composition for the detection of microorganisms in a sample
USD423679S (en) 1998-06-12 2000-04-25 Tafco Medical Products LLC Medical organizer
US6306658B1 (en) 1998-08-13 2001-10-23 Symyx Technologies Parallel reactor with internal sensing
US6485692B1 (en) 1998-12-04 2002-11-26 Symyx Technologies, Inc. Continuous feed parallel reactor
CA2317743A1 (en) 1998-12-11 2000-06-22 Paul Mansky Sensor array-based system and method for rapid materials characterization
DE19903506C2 (de) * 1999-01-29 2002-04-04 Inst Chemo Biosensorik Verfahren, Gefäß und Vorrichtung zur Überwachung der Stoffwechselaktivität von Zellkulturen in flüssigen Medien
JP2002537851A (ja) * 1999-03-09 2002-11-12 アコルディス インダストリアル ファイバース ゲゼルシャフト ミット ベシュレンクテル ハフツング 作用物質のインビトロテスト法、その装置および使用
US6078698A (en) 1999-09-20 2000-06-20 Flir Systems, Inc. System for reading data glyphs
FR2792333B1 (fr) 1999-04-14 2003-01-24 Labonord Dispositif de depot de cellules sur une plaque d'analyse
US7795012B2 (en) 1999-05-06 2010-09-14 Micronas Gmbh Device for performing analysis on cell cultures
DE19920811B4 (de) 1999-05-06 2004-08-19 Micronas Gmbh Vorrichtung zur Durchführung von Untersuchungen an Zellkulturen
USD466219S1 (en) 1999-09-13 2002-11-26 Micronic B.V. Carrier for test-tubes
US6395555B1 (en) 1999-10-14 2002-05-28 David F. Wilson Method and apparatus for determining the effect of a drug on cells
USD438631S1 (en) 1999-12-21 2001-03-06 Compucyte Corporation Reagent treatment cartridge
USD438632S1 (en) 1999-12-21 2001-03-06 Compucyte Corporation Multi-well reagent cartridge for treating a sample
USD438633S1 (en) 1999-12-21 2001-03-06 Compucyte Corporation Reagent cartridge for treating a sample
US7485454B1 (en) 2000-03-10 2009-02-03 Bioprocessors Corp. Microreactor
AUPQ653000A0 (en) * 2000-03-28 2000-04-20 Cook Incorporated Perfusion incubator
US6880158B1 (en) 2000-04-10 2005-04-12 International Business Machines Corporation Network processor services architecture that is platform and operating system independent
JP2003532877A (ja) 2000-05-08 2003-11-05 アンテルユニヴェルシテール・ミクロ−エレクトロニカ・サントリュム・ヴェー・ゼッド・ドゥブルヴェ ハイスループットリードプロファイリング方法
WO2001098754A1 (en) 2000-06-22 2001-12-27 Atto Instruments Llc High efficiency cell analysis system and high throughput drug screening system
WO2002000336A2 (en) 2000-06-28 2002-01-03 Illumina, Inc. Composite arrays utilizing microspheres with a hybridization chamber
JP2002010777A (ja) 2000-06-30 2002-01-15 Precision System Science Co Ltd 反応容器、反応装置および反応液の温度制御方法
US6770470B2 (en) 2000-07-22 2004-08-03 Inbionet Corporation Strain for decomposing TMAH, and method of wastewater treatment using the same
GB0019176D0 (en) 2000-08-05 2000-09-27 Cambridge Material Science Lim Monitoring thermal events
EP1309719B2 (de) 2000-08-14 2022-09-07 University of Maryland at Baltimore County Bioreaktor und bioverfahrenstechnik
US6653124B1 (en) 2000-11-10 2003-11-25 Cytoplex Biosciences Inc. Array-based microenvironment for cell culturing, cell monitoring and drug-target validation
US20020098592A1 (en) 2000-11-17 2002-07-25 Flir Systems Boston, Inc. Apparatus and methods for infrared calorimetric measurements
US20020132360A1 (en) 2000-11-17 2002-09-19 Flir Systems Boston, Inc. Apparatus and methods for infrared calorimetric measurements
US20040110301A1 (en) 2000-11-17 2004-06-10 Neilson Andy C Apparatus and methods for measuring reaction byproducts
AU2002249778A1 (en) 2000-11-17 2002-08-12 Thermogenic Imaging, Inc. Apparatus and methods for infrared calorimetric measurements
WO2002072423A1 (en) 2001-03-09 2002-09-19 Biomicro Systems, Inc. Microplate lid
US20030077817A1 (en) 2001-04-10 2003-04-24 Zarur Andrey J. Microfermentor device and cell based screening method
US7118909B2 (en) 2001-05-30 2006-10-10 Gevaert Matthew R Apparatus and method for biomaterial assay
DE10136005C1 (de) 2001-06-06 2002-11-28 Infineon Technologies Ag Halbleiter-Temperatursensor vom Ausbreitungswiderstands-Typ
US20030059807A1 (en) 2001-06-07 2003-03-27 Proligo Llc Microcalorimetric detection of analytes and binding events
US6794191B2 (en) 2001-06-25 2004-09-21 Photonic Systems Process for forming polymer structures containing an oxygen sensor
WO2003004596A1 (fr) 2001-07-06 2003-01-16 Precision System Science Co., Ltd. Recipient de reaction et dispositif de reaction
US6766817B2 (en) 2001-07-25 2004-07-27 Tubarc Technologies, Llc Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action
USD461554S1 (en) 2001-08-03 2002-08-13 3088081 Canada Inc. Test tube rack
USD467080S1 (en) 2001-09-07 2002-12-17 Wade N. Zimmerman Rocker arm organizer tray
WO2003022421A2 (en) * 2001-09-07 2003-03-20 Corning Incorporated Microcolumn-platform based array for high-throughput analysis
US20040086888A1 (en) 2001-10-18 2004-05-06 Kornblith Paul L Method for tandem genomic/proteomic analysis of proliferating cells
DE10201259A1 (de) * 2002-01-15 2003-08-28 Augustinus Bader Vorrichtung zum Züchten oder Kultivieren von Zellen in einem dosenartigen Behälter
US20040077075A1 (en) 2002-05-01 2004-04-22 Massachusetts Institute Of Technology Microfermentors for rapid screening and analysis of biochemical processes
USD486580S1 (en) 2002-06-24 2004-02-10 Ussama M. Abdel-Model Rack for holding tissue cell culture flasks
USD492419S1 (en) 2002-09-20 2004-06-29 Dade Behring Inc. Stackable aliquot vessel array
JP2004113092A (ja) * 2002-09-25 2004-04-15 Shimadzu Corp 細胞培養チップ
US20040107986A1 (en) 2002-12-06 2004-06-10 Neilson Andy C. High throughput microcalorimeter systems and methods
WO2004065618A2 (en) 2003-01-16 2004-08-05 Thermogenic Imaging Methods and devices for monitoring cellular metabolism in microfluidic cell-retaining chambers
FI115060B (fi) 2003-04-22 2005-02-28 Chip Man Technologies Oy Analyysi- ja kasvatuslaitteisto
DE10329983A1 (de) 2003-06-27 2005-03-31 Siemens Ag Mikroreaktorsystem mit einer Reaktionsräume aufweisenden Trägerplatte und Verfahren zum Betrieb desselben
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
DE10346451B4 (de) 2003-10-03 2007-08-02 Bionas Gmbh Verfahren zur Überwachung von Veränderungen und Zuständen in Reaktionskammern
US20070087401A1 (en) * 2003-10-17 2007-04-19 Andy Neilson Analysis of metabolic activity in cells using extracellular flux rate measurements
US8658349B2 (en) 2006-07-13 2014-02-25 Seahorse Bioscience Cell analysis apparatus and method
JP4445765B2 (ja) * 2004-02-05 2010-04-07 グンゼ株式会社 細胞培養装置
USD529184S1 (en) 2004-09-01 2006-09-26 The Automation Partnership (Cambridge) Filter block
FR2881434B1 (fr) * 2005-02-02 2007-05-11 Coletica Sa Dispositif de support de culture de cellules
USD566291S1 (en) 2005-05-03 2008-04-08 Handylab, Inc. Microfluidic cartridge
JP5261189B2 (ja) 2005-12-14 2013-08-14 ビーエーエスエフ コーポレーション Nox選択的触媒還元効率の改善されたゼオライト触媒
US20080031774A1 (en) 2006-03-13 2008-02-07 Sage Science, Inc. Apparatus for Guiding Sample and Reagent Manipulations and Receptacles for Holding Same
USD565742S1 (en) 2006-03-27 2008-04-01 Handylab, Inc. Microfluidic cartridge
JP2008092935A (ja) * 2006-10-13 2008-04-24 Otake:Kk 密封培養容器にポンプ機能を設けた培養装置
USD624661S1 (en) 2008-02-26 2010-09-28 Bruker Biospin Ag Holder for sample containers
USD613418S1 (en) 2008-07-23 2010-04-06 Smiths Medical Asd, Inc. Tray assembly
JP2010041988A (ja) * 2008-08-12 2010-02-25 Able Corp 培養リアクター
USD619258S1 (en) 2008-09-10 2010-07-06 Carl Zeiss Vision Gmbh Inlay for transport tray for spectable lenses and spectacle lens blanks
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
USD628306S1 (en) 2009-01-23 2010-11-30 Roche Diagnostics Operations, Inc. Microtiter plate
USD632402S1 (en) 2009-02-19 2011-02-08 Roche Diagnostics Operations, Inc. Combination of reagent holder and parts
USD617468S1 (en) 2009-05-27 2010-06-08 Inverness Medical Innovations, Inc. Test strip
USD628305S1 (en) 2009-07-14 2010-11-30 Medical Research Council Sitting-drop microwell plate for crystalization
USD618821S1 (en) 2009-07-30 2010-06-29 Ferrosan A/S Tray
USD631557S1 (en) 2009-10-02 2011-01-25 Universal Bio Research Co., Ltd Cartridge container for separating magnetic particles
USD657473S1 (en) 2009-12-25 2012-04-10 Hitachi Plant Technologies, Ltd. Reagent container
USD679025S1 (en) 2010-01-22 2013-03-26 Biotix, Inc. Anti-static pipette tip tray
EP2529238A4 (de) 2010-01-28 2014-10-08 The Regents Of The University Of Michigan Hängende tropfvorrichtungen, -systeme und/oder -verfahren
USD672053S1 (en) 2010-05-07 2012-12-04 Anp Technologies, Inc. Multi-lateral flow assay strip carrier assembly
USD669594S1 (en) 2010-08-31 2012-10-23 Canon U.S. Life Sciences, Inc. Cartridge assembly
USD673293S1 (en) 2010-10-22 2012-12-25 T2 Biosystems, Inc. Modular cartridge assembly
USD674112S1 (en) 2010-10-22 2013-01-08 T2 Biosystems, Inc. Modular cartridge assembly
USD686311S1 (en) 2011-05-10 2013-07-16 Fujifilm Corporation Cartridge for immunochromatographic test device
USD651802S1 (en) 2011-06-14 2012-01-10 Falcon Plastics, Inc. Stackable tray for holding cartridges
USD714957S1 (en) 2011-07-28 2014-10-07 Ge Healthcare Uk Limited Sample card magazine
USD696419S1 (en) 2011-11-09 2013-12-24 Dynex Technologies, Inc. Reagent kit insert
EP2636452A1 (de) 2012-03-06 2013-09-11 Greiner Bio-One GmbH Ausfleckplatte und Verfahren zu ihrer Herstellung
USD686749S1 (en) 2012-04-20 2013-07-23 Stratec Biomedical Ag Rack for holding sheaths
BR302012005754S1 (pt) 2012-05-07 2014-05-27 Terumo Corp Configuração aplicada a recipiente para seringa médica
USD701972S1 (en) 2012-09-28 2014-04-01 Sysmex Corporation Storage case for sample plate
USD720468S1 (en) 2013-01-28 2014-12-30 Advanced Animal Diagnostics Sample collection device assembly
USD694906S1 (en) 2013-01-30 2013-12-03 Apothecary Products, Inc. Pill fill tray
USD694904S1 (en) 2013-01-31 2013-12-03 Medtrain Technologies, Llc Three well culture plate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014078379A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385700A1 (de) * 2017-04-06 2018-10-10 Agilent Technologies, Inc. Verfahren und vorrichtung zur messung physiologischer eigenschaften biologischer proben
US11639925B2 (en) 2017-04-06 2023-05-02 Agilent Technologies, Inc. Method and apparatus for measuring physiological properties of biological samples
EP4155709A1 (de) * 2021-09-28 2023-03-29 Bayer AG Biomolekulare online-interaktionsanalyse zur überwachung oder steuerung von bioprozessen

Also Published As

Publication number Publication date
WO2014078379A3 (en) 2014-07-17
JP6326058B2 (ja) 2018-05-16
JP2016503299A (ja) 2016-02-04
EP2920292B1 (de) 2017-01-11
US20140170671A1 (en) 2014-06-19
WO2014078379A2 (en) 2014-05-22
CN104471052A (zh) 2015-03-25
CN104471052B (zh) 2017-06-13
US9494577B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
US9494577B2 (en) Apparatus and methods for three-dimensional tissue measurements based on controlled media flow
Dornhof et al. Microfluidic organ-on-chip system for multi-analyte monitoring of metabolites in 3D cell cultures
US10359418B2 (en) Cell analysis apparatus and method
US20070087401A1 (en) Analysis of metabolic activity in cells using extracellular flux rate measurements
US8709793B2 (en) Bioreactor device, and method and system for fabricating tissues in the bioreactor device
EP2322913B1 (de) Verfahren und Vorrichtung zur Messung mehrerer physiologischer Eigenschaften von Zellen
JP2007505316A5 (de)
US11680241B2 (en) Perfusion enabled bioreactors
Müller et al. Measurement of respiration and acidification rates of mammalian cells in thermoplastic microfluidic devices
US20160178618A1 (en) 3d tissue model for spatially correlated analysis of biochemical, physiological and metabolic micro-environments
Bussooa et al. Real-time monitoring of oxygen levels within thermoplastic Organ-on-Chip devices
Szmelter et al. 96-well oxygen control using a 3D-printed device
Brischwein et al. Microphysiometry
KR20220150916A (ko) 세포 처리를 위한 생물반응기
WO2022083964A1 (en) System for monitoring three-dimensional cell cultures
AU2018200697A1 (en) Method and device for calibration of biological flux
JP2008301758A (ja) 細胞培養装置
US11926812B2 (en) Pressure-driven, adjustable throughput fluidics for tissue and cell perifusions
JP2018189474A (ja) バイオチップ及びバイオアッセイ装置並びにバイオアッセイ方法
WO2024092347A1 (en) Cell culture devices
Lin et al. Cell metabolite analysis on microfluidic platform
WO2023086372A1 (en) Wellplate apparatus and method for filling same
WO2023081354A1 (en) Apparatus and methods for generating and analyzing three-dimensional cellular materials
CN116496897A (zh) 可形成气-液界面的共培养微流控芯片气体暴露装置及其应用
Pinelis A high-throughput method for in vitro generation and studies of oxygen microgradients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150615

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013016600

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12M0001320000

Ipc: C12M0001020000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12M 1/32 20060101ALI20160711BHEP

Ipc: C12M 1/00 20060101ALI20160711BHEP

Ipc: C12M 1/12 20060101ALI20160711BHEP

Ipc: G01N 21/64 20060101ALI20160711BHEP

Ipc: C12M 1/02 20060101AFI20160711BHEP

Ipc: C12M 1/34 20060101ALI20160711BHEP

Ipc: B01L 3/00 20060101ALI20160711BHEP

Ipc: G01N 33/50 20060101ALI20160711BHEP

INTG Intention to grant announced

Effective date: 20160801

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEAHORSE BIOSCIENCE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGILENT TECHNOLOGIES, INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 861290

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013016600

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170111

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 861290

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170511

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170411

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170412

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170511

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170411

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013016600

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

26N No opposition filed

Effective date: 20171012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013016600

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171113

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180731

Ref country code: BE

Ref legal event code: MM

Effective date: 20171130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180602

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231006

Year of fee payment: 11